-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the continuous development of China's pharmaceutical innovation policy, favorable development environment, and increased investment in research and development by local pharmaceutical companies, the recognition of local innovative drug companies by international pharmaceutical giants has begun to increase
.
In this context, the cooperation between Chinese and foreign pharmaceutical companies has gradually become a common and meaningful event
.
It is understood that with the advancement of the cooperation project, the fruits of the R&D cooperation between Chinese and foreign pharmaceutical companies are gradually being produced
.
For example, on February 2 this year, the innovative PD-1 inhibitor Daboshu (sintilimab injection) jointly developed by Eli Lilly and Cinda Biopharmaceuticals combined with pemetrexed and platinum-based chemotherapy for epidermal growth factor receptors (EGFR) gene mutation negative and anaplastic lymphoma kinase (ALK) negative non-squamous non-small cell lung cancer (nsqNSCLC) new indications for the first-line treatment have been officially approved by the State Food and Drug Administration
.
It is worth mentioning that under the influence of this, Chinese and foreign pharmaceutical companies have "handed in" more and more frequently since this year.
Recently, many Chinese and foreign pharmaceutical companies have announced that they will cooperate in the research and development of new drugs
.
Deck Pharmaceuticals and Bristol-Myers Squibb will jointly develop a combination therapy On December 13, Deck Pharmaceuticals Co.
, Ltd.
("Decki Pharmaceuticals") announced that the company and Bristol-Myers Squibb have reached a clinical cooperation agreement to jointly Develop a project to evaluate the safety, pharmacokinetics and preliminary efficacy of ATG-017 combined with Bristol-Myers Squibb's PD-1 checkpoint inhibitor Odivo® (nivolumab) for the treatment of advanced solid tumors The open phase 1/2 clinical study
.
Data show that ATG-017 is a selective oral inhibitor that acts on extracellular signal-regulated kinase 1 and 2 (ERK1/2), while Odivo® is a PD-1 checkpoint inhibitor
.
According to the agreement, Deqi Pharmaceuticals will be responsible for the development of the clinical trial and provide financial support, and will have the global commercialization and development rights of ATG-017; and Bristol-Myers Squibb will provide dose ramping and dose expansion of the combination therapy Odivo® needed in research
.
Regal Pharmaceuticals and Eli Lilly of the United States reached a strategic cooperation On December 10, Regal Pharmaceuticals and Eli Lilly of the United States jointly announced that they have reached a research cooperation and patent licensing agreement.
The two parties will conduct preclinical drug development and clinical research in the next few years.
In close cooperation with commercialization, we will jointly develop innovative therapies for metabolic diseases
.
According to the terms of the agreement, Rieger Pharmaceuticals granted Eli Lilly the United States a license for the intellectual property rights of Rieger Pharmaceuticals, and Eli Lilly can choose to extend the license
.
Eli Lilly will be responsible for clinical development, production and commercialization outside of Greater China (including Mainland China, Hong Kong, Macau and Taiwan), while Ruige Pharmaceutical will retain the aforementioned rights and interests in Greater China
.
With this cooperation, Rieger Pharmaceuticals is expected to receive a total of US$50 million in advance payments, including some equity investment; in addition, it will receive up to US$1.
5 billion in potential preclinical, clinical development and commercialization milestone payments, as well as individual positions.
Count down to the lower double-digit global sales share
.
Conclusion In general, with the support of a series of policies to encourage innovative drug research and development, such as centralized procurement and medical insurance negotiations, China's pharmaceutical industry is continuously accelerating its transformation towards innovation
.
In the future, with the continuous improvement of China's innovative drug research and development capabilities, the cooperation events between Chinese and foreign pharmaceutical companies will continue to increase
.
.
In this context, the cooperation between Chinese and foreign pharmaceutical companies has gradually become a common and meaningful event
.
It is understood that with the advancement of the cooperation project, the fruits of the R&D cooperation between Chinese and foreign pharmaceutical companies are gradually being produced
.
For example, on February 2 this year, the innovative PD-1 inhibitor Daboshu (sintilimab injection) jointly developed by Eli Lilly and Cinda Biopharmaceuticals combined with pemetrexed and platinum-based chemotherapy for epidermal growth factor receptors (EGFR) gene mutation negative and anaplastic lymphoma kinase (ALK) negative non-squamous non-small cell lung cancer (nsqNSCLC) new indications for the first-line treatment have been officially approved by the State Food and Drug Administration
.
It is worth mentioning that under the influence of this, Chinese and foreign pharmaceutical companies have "handed in" more and more frequently since this year.
Recently, many Chinese and foreign pharmaceutical companies have announced that they will cooperate in the research and development of new drugs
.
Deck Pharmaceuticals and Bristol-Myers Squibb will jointly develop a combination therapy On December 13, Deck Pharmaceuticals Co.
, Ltd.
("Decki Pharmaceuticals") announced that the company and Bristol-Myers Squibb have reached a clinical cooperation agreement to jointly Develop a project to evaluate the safety, pharmacokinetics and preliminary efficacy of ATG-017 combined with Bristol-Myers Squibb's PD-1 checkpoint inhibitor Odivo® (nivolumab) for the treatment of advanced solid tumors The open phase 1/2 clinical study
.
Data show that ATG-017 is a selective oral inhibitor that acts on extracellular signal-regulated kinase 1 and 2 (ERK1/2), while Odivo® is a PD-1 checkpoint inhibitor
.
According to the agreement, Deqi Pharmaceuticals will be responsible for the development of the clinical trial and provide financial support, and will have the global commercialization and development rights of ATG-017; and Bristol-Myers Squibb will provide dose ramping and dose expansion of the combination therapy Odivo® needed in research
.
Regal Pharmaceuticals and Eli Lilly of the United States reached a strategic cooperation On December 10, Regal Pharmaceuticals and Eli Lilly of the United States jointly announced that they have reached a research cooperation and patent licensing agreement.
The two parties will conduct preclinical drug development and clinical research in the next few years.
In close cooperation with commercialization, we will jointly develop innovative therapies for metabolic diseases
.
According to the terms of the agreement, Rieger Pharmaceuticals granted Eli Lilly the United States a license for the intellectual property rights of Rieger Pharmaceuticals, and Eli Lilly can choose to extend the license
.
Eli Lilly will be responsible for clinical development, production and commercialization outside of Greater China (including Mainland China, Hong Kong, Macau and Taiwan), while Ruige Pharmaceutical will retain the aforementioned rights and interests in Greater China
.
With this cooperation, Rieger Pharmaceuticals is expected to receive a total of US$50 million in advance payments, including some equity investment; in addition, it will receive up to US$1.
5 billion in potential preclinical, clinical development and commercialization milestone payments, as well as individual positions.
Count down to the lower double-digit global sales share
.
Conclusion In general, with the support of a series of policies to encourage innovative drug research and development, such as centralized procurement and medical insurance negotiations, China's pharmaceutical industry is continuously accelerating its transformation towards innovation
.
In the future, with the continuous improvement of China's innovative drug research and development capabilities, the cooperation events between Chinese and foreign pharmaceutical companies will continue to increase
.
